Trial Profile

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine
Indications Bladder cancer; Renal cancer; Urethral cancer; Urogenital cancer
Focus Registrational; Therapeutic Use
Acronyms NILE
Sponsors AstraZeneca; AstraZeneca AB

24 Sep 2024 Planned primary completion date changed from 30 Aug 2024 to 30 Jun 2025.
09 Feb 2024 Planned End Date changed from 30 Oct 2025 to 30 Jun 2025.
09 Feb 2024 Planned primary completion date changed from 15 Jan 2024 to 30 Aug 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com